Pathogenesis of hand eczema.

CONCLUSION: The exact understanding of the individual pathogenesis in single hand eczema patients is essential in order to provide specific advice on allergen avoidance, skin protection and basic treatment and to initiate appropriate therapeutic measures. PMID: 31501971 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research

Related Links:

Authors: Cork MJ, Danby SG, Ogg GS Abstract Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin condition associated with a significant health-related and socioeconomic burden, and is characterized by intense itch, disruption of the skin barrier, and upregulation of type 2-mediated immune responses. The United Kingdom (UK) has a high prevalence of AD, affecting 11-20% of children and 5-10% of adults. Approximately 2% of all cases of childhood AD in the UK are severe. Despite this, most AD treatments are performed at home, with little contact with healthcare providers or services. Her...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
AbstractIntroductionThe Patient-Oriented Eczema Measure (POEM) assesses patient-reported frequency of atopic dermatitis (AD) symptoms, while the Children ’s Dermatology Life Quality Index (CDLQI) measures the impact of skin disease on health-related quality of life (HRQoL) in children. There is currently no threshold for clinically meaningful within-person change in POEM or CDLQI scores in adolescents. Here we empirically derive within-person thres holds of meaningful within-person change in POEM and CDLQI scores in adolescents with moderate-to-severe AD.MethodsData were used from a phase 3, randomized, double-blind,...
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Conclusions: It seems that the colonisation of the lesioned skin, healthy skin and the anterior nares by S. aureus is related with higher tIgE serum concentration, which translates to more severe course of the disease. Significantly increased SEA-IgE and SEB-IgE concentrations were observed in the patients whose tIgE serum concentration was statistically higher. PMID: 31616226 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Capsule Summary: Ruxolitinib cream improved Eczema Area Severity Index and Investigator ’s Global Assessment responses in patients with atopic dermatitis (AD), with rapid, sustained improvement in itch. Ruxolitinib cream may offer a novel and effective treatment for AD.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: The prevalence of p-phenylenediamine allergy remains high among patients with contact eczema. Risk factors for p-phenylenediamine contact allergy are consistent with previous reports. PMID: 31627850 [PubMed - as supplied by publisher]
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Authors: Tags: Actas Dermosifiliogr Source Type: research
CONCLUSIONS: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candida...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children. J Drugs Dermatol. 2019;18(10):1038-1045. PMID: 31584783 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Conditions:   Atopic Dermatitis;   Atopic Eczema Interventions:   Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo;   Drug: Protopic, tacrolimus ointment 0.1% Sponsors:   Jacob Thyssen;   LEO Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Dermatitis | Dermatology | Eczema | Genetics | Molecular Biology | Skin